AQST is trading at $4.39 (7.1% down) as investors take profits following a sharp 14.53% rally triggered by strong Q1 earnings results.
- The stock surged yesterday after the company reported 66% revenue growth, reaffirmed its 2026 guidance, and detailed a $150M refinancing plan.
- Management highlighted a de-risked regulatory path for Anaphylm, which served as a primary catalyst for the previous session's gains.
- Today's pullback reflects a normalization of the share price amid a broader risk-off sentiment across major market indices.